Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.80 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610932 | 0.86 | ALDH1A1 (0.81) | ALDH1A1LMNASMN1; SMN2HTTMAPT | |
| SCHEMBL13623622 | 0.84 | LMNA (0.67) | ALDH1A1LMNASMN1; SMN2MEN1HTT | |
| SCHEMBL12203800 | 0.78 | MAPT (0.65) | ALDH1A1LMNASMN1; SMN2MEN1HTT | |
| SCHEMBL7930198 | 0.75 | MAPT (0.78) | ALDH1A1LMNASMN1; SMN2MEN1HTT | |
| SCHEMBL13610834 | 0.75 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL12195242 | 0.74 | HTT (0.56) | ALDH1A1LMNASMN1; SMN2MEN1HTT | |
| SCHEMBL11887749 | 0.72 | PTGDR2 (0.75) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5118599 | 0.71 | PTGDR2 (0.76) | ALDH1A1MEN1KMT2ANPC1POLB | |
| SCHEMBL13768080 | 0.71 | ALDH1A1 (0.63) | ALDH1A1LMNASMN1; SMN2MEN1HTT | |
| SCHEMBL4296199 | 0.71 | L3MBTL1 (0.91) | ALDH1A1LMNASMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | ALDH1A1 2368/4885LMNA 2982/4885SMN1; SMN2 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.